on MindBio Therapeutics (isin : CA60256C1086)
MindBio Therapeutics CEO Updates Shareholders on Clinical Trials Progress
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), a biopharmaceutical company specializing in psychiatric medicine, provided an update to shareholders from CEO Justin Hanka.
MindBio is advancing two Phase 2B clinical trials for its lead drug, MB22001. The trials target Major Depressive Disorder and Advanced Stage Cancer-related depression and anxiety. Both trials are progressing well with scheduled patient dosing and are expected to finish in 2025.
A third Phase 2B clinical trial targeting Pre-Menstrual Syndrome and Pre-Menstrual Dysphoric Disorder has been approved to start dosing. Initial baseline data collection is planned for a smaller Phase 1/2a trial.
MindBio is notable for its sub-hallucinogenic microdosing model, differentiating it from peers. The company targets scalable, accessible, and affordable treatments and aims for a senior exchange listing after Phase 2B trials.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MindBio Therapeutics news